Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas (Q33296232)

25 July 2017

Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas (English)

1 reference

25 July 2017

1 reference

8

Bernard Meunier

1 reference

25 July 2017

Francoise Bouet-Toussaint

1

1 reference

25 July 2017

Florian Cabillic

2

1 reference

25 July 2017

Olivier Toutirais

3

1 reference

25 July 2017

Matthieu Le Gallo

4

1 reference

25 July 2017

Cécile Thomas de la Pintière

5

1 reference

25 July 2017

Pascale Daniel

6

1 reference

25 July 2017

Noëlle Genetet

7

1 reference

25 July 2017

Eric Dupont-Bierre

9

1 reference

25 July 2017

Karim Boudjema

10

1 reference

25 July 2017

Véronique Catros

11

1 reference

25 July 2017

1 September 2007

1 reference

Cancer Immunology, Immunotherapy

25 July 2017

1 reference

25 July 2017

57

1 reference

25 July 2017

531-539

1 reference

25 July 2017

4

1 reference

Opioid-induced bowel dysfunction: pathophysiology and potential new therapies

25 July 2017

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Treatment of opioid-induced gut dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

A review of the potential role of methylnaltrexone in opioid bowel dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Postoperative urinary retention. I. Incidence and predisposing factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Patient-controlled analgesia and urinary retention following lower limb joint replacement: prospective audit and logistic regression analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Intestinal motility disturbances in intensive care patients pathogenesis and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

The role of endogenous opioids in the control of gastrointestinal motility: predictions from in vitro modelling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

The opioid system in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Function of opioids in the enteric nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Insights into opioid action in the intestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Morphine contracts the guinea pig ileal circular muscle by interfering with a nitric oxide mediated tonic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Inhibition of stimulated fluid secretion in the rat small and large intestine by opiate agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Involvement of mu- and kappa-, but not delta-, opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

The central and peripheral influences of opioids on gastrointestinal propulsion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Mechanisms and treatment of postoperative ileus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Mechanisms of postoperative ileus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Intrathecal opioids and lower urinary tract function: a urodynamic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Management of opioid-induced gastrointestinal effects in patients receiving palliative care

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Incidence, prevalence, and management of opioid bowel dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Multimodal strategies to improve surgical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Basic and clinical pharmacology of new motility promoting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Alvimopan: a peripherally acting mu-opioid receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Preclinical studies of opioids and opioid antagonists on gastrointestinal function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Oral naloxone reduces constipation but not antinociception from oral morphine in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Oral naloxone reverses opioid-associated constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Low-dose oral naloxone reverses opioid-induced constipation and analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Opioid-induced delay in gastric emptying: a peripheral mechanism in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Oral methylnaltrexone for opioid-induced constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Methylnaltrexone for opioid-induced constipation in advanced illness

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Effects of methylnaltrexone on morphine-induced cough suppression in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

Alvimopan, a selective peripherally acting mu-opioid antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14750708.5.4.531

21 January 2018

Identifiers

DOI

10.2217/14750708.5.4.531

1 reference

25 July 2017

1 reference